MedTrace Logo

Smoking Relapse Prevention Among COPD Ex-smokers

NCT02888444 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2019-05-15

No results posted yet for this study

Summary

A placebo-controlled trial to determine whether recent ex-smokers with COPD who successfully stop smoking after taking varenicline are less likely to relapse back to smoking if they continue using varenicline for a further 12 weeks

Conditions

Interventions

DRUG

Varenicline

Two 0.5mg tablets taken twice daily

BEHAVIORAL

Behavioural support

Consisting of the study-specific doctor delivering relapse prevention orientated behavioural support at the time of consultation, plus six 10-15 minute calls over the 12 weeks delivered by a research assistant.

DRUG

Placebo

Two 0.5mg tablets taken twice daily

Sponsors & Collaborators

  • University of Auckland, New Zealand

    lead OTHER

Principal Investigators

  • Natalie Walker, PhD · University of Auckland, New Zealand

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-31
Primary Completion
2018-04-13
Completion
2018-04-13

Countries

  • New Zealand

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02888444 on ClinicalTrials.gov